Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Borg-Bartolo, R. Boyapati, J. Satsangi, R. Kalla (2020)
Precision medicine in inflammatory bowel disease: concept, progress and challengesF1000Research, 9
S. Targan, S. Hanauer, S. Deventer, L. Mayer, D. Present, T. Braakman, K. DeWoody, T. Schaible, P. Rutgeerts (1997)
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 337
Prashanth Rawla, T. Sunkara, J. Raj (2018)
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectivesJournal of Inflammation Research, 11
M. Raad, N. Chams, A. Sharara (2016)
New and Evolving Immunotherapy in Inflammatory Bowel DiseaseInflammatory Intestinal Diseases, 1
M. Bortlík, D. Ďuricová, K. Malíčková, N. Machková, Eva Bouzkova, L. Hrdlička, A. Komárek, M. Lukáš (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.Journal of Crohn's & colitis, 7 9
G. D'Haens, S. Vermeire, G. Lambrecht, F. Baert, P. Bossuyt, B. Pariente, A. Buisson, Y. Bouhnik, J. Filippi, Janneke Woude, P. Hootegem, J. Moreau, E. Louis, D. Franchimont, M. Vos, F. Mana, L. Peyrin-Biroulet, H. Brixi, M. Allez, P. Caenepeel, A. Aubourg, B. Oldenburg, M. Pierik, A. Gils, S. Chevret, D. Laharie (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.Gastroenterology, 154 5
E. Maser, Renata Villela, M. Silverberg, G. Greenberg (2006)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 4 10
S. Vermeire, A. Gils, P. Accossato, S. Lula, A. Marren (2018)
Immunogenicity of biologics in inflammatory bowel diseaseTherapeutic Advances in Gastroenterology, 11
K. Karlinger, T. Györke, Ernő Makö, Á. Mester, Z. Tarján (2000)
The epidemiology and the pathogenesis of inflammatory bowel disease.European journal of radiology, 35 3
M. Lémann, J. Mary, B. Duclos, M. Veyrac, J. Dupas, J. Delchier, D. Laharie, J. Moreau, G. Cadiot, L. Picon, A. Bourreille, I. Sobahni, J. Colombel (2006)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.Gastroenterology, 130 4
(2017)
American Gastroenterological Association Institute Clinical Guidelines, American Gastroenterological Association institute guideline on therapeutic drug monitoring in inflammatory bowel disease
C. Steenholdt, Madeline Frederiksen, K. Bendtzen, M. Ainsworth, O. Thomsen, J. Brynskov (2016)
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 50
L. Guidi, D. Pugliese, T. Tonucci, Alexandra Berrino, B. Tolusso, M. Basile, L. Cantoro, P. Balestrieri, F. Civitelli, L. Bertani, M. Marzo, C. Felice, E. Gremese, F. Costa, F. Viola, M. Cicala, A. Kohn, A. Gasbarrini, G. Rapaccini, M. Ruggeri, A. Armuzzi (2018)
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre StudyJournal of Crohn's and Colitis, 12
S. Paramsothy, A. Rosenstein, S. Mehandru, J. Colombel (2018)
The current state of the art for biological therapies and new small molecules in inflammatory bowel diseaseMucosal Immunology, 11
D. Wishart, Y. Feunang, Anchi Guo, Elvis Lo, A. Marcu, J. Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, Nazanin Assempour, Ithayavani Iynkkaran, Yifeng Liu, Adam Maciejewski, Nicola Gale, Alex Wilson, Lucy Chin, Ryan Cummings, Diana Le, Allison Pon, Craig Knox, Michael Wilson (2017)
DrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Research, 46
S. Paul, X. Roblin, L. Peyrin-Biroulet (2015)
Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 42
K. Papamichael, Karen Chachu, Ravy Vajravelu, B. Vaughn, Josephine Ni, M. Osterman, A. Cheifetz (2017)
Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of InfliximabClinical Gastroenterology & Hepatology, 15
G. Bartelds, C. Krieckaert, M. Nurmohamed, P. Schouwenburg, W. Lems, J. Twisk, B. Dijkmans, L. Aarden, G. Wolbink (2011)
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.JAMA, 305 14
A. Assa, M. Matar, D. Turner, E. Broide, B. Weiss, O. Ledder, A. Guz-Mark, F. Rinawi, Shlomi Cohen, C. Topf-Olivestone, R. Shaoul, B. Yerushalmi, R. Shamir (2019)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring.Gastroenterology
B. Xia, J. Crusius, S. Meuwissen, AS Pe?a (1998)
Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.World journal of gastroenterology, 4 5
J. Côté-Daigneault, M. Bouin, R. Lahaie, J. Colombel, P. Poitras (2015)
Biologics in inflammatory bowel disease: what are the data?United European Gastroenterology Journal, 3
F. Cornillie, S. Hanauer, R. Diamond, Jianping Wang, K. Tang, Zhenhua Xu, P. Rutgeerts, S. Vermeire (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trialGut, 63
Vincent Billioud, W. Sandborn, L. Peyrin-Biroulet (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewThe American Journal of Gastroenterology, 106
C. Seow, A. Newman, S. Irwin, A. Steinhart, M. Silverberg, G. Greenberg (2009)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut, 59
C. Lamb, C. Lamb, N. Kennedy, T. Raine, P. Hendy, P. Hendy, Philip Smith, J. Limdi, J. Limdi, B. Hayee, BuʼHussain Hayee, M. Lomer, M. Lomer, G. Parkes, G. Parkes, C. Selinger, C. Selinger, K. Barrett, R. Davies, Cathy Bennett, Stuart Gittens, M. Dunlop, M. Dunlop, O. Faiz, A. Fraser, V. Garrick, Paul Johnston, M. Parkes, J. Sanderson, J. Sanderson, H. Terry, D. Gaya, D. Gaya, T. Iqbal, T. Iqbal, S. Taylor, S. Taylor, Melissa Smith, Melissa Smith, M. Brookes, R. Hansen, A. Hawthorne (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adultsGut, 68
M. Fakhoury, R. Negrulj, A. Mooranian, H. Al‐Salami (2014)
Inflammatory bowel disease: clinical aspects and treatmentsJournal of Inflammation Research, 7
V. Strand, A. Balsa, J. Al-Saleh, L. Barile-fabris, T. Horiuchi, T. Takeuchi, S. Lula, C. Hawes, B. Kola, L. Marshall (2017)
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic ReviewBiodrugs, 31
C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck, J. Fallingborg, L. Christensen, G. Pedersen, J. Kjeldsen, B. Jacobsen, A. Oxholm, J. Kjellberg, K. Bendtzen, M. Ainsworth (2013)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trialGut, 63
G. D'Haens (2007)
Risks and benefits of biologic therapy for inflammatory bowel diseasesGut, 56
J. Gisbert, J. Panés (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A ReviewThe American Journal of Gastroenterology, 104
M. Wadhwa, I. Knezevic, Hye-Na Kang, R. Thorpe (2015)
Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility.Biologicals : journal of the International Association of Biological Standardization, 43 5
N. Casteele, M. Ferrante, G. Assche, V. Ballet, G. Compernolle, K. Steen, S. Simoens, P. Rutgeerts, A. Gils, S. Vermeire (2015)
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.Gastroenterology, 148 7
PURPOSE OF THE REVIEW:Here we critically evaluate the literature on immunotherapy failure in inflammatory bowel disease patients. In particular anti-drug antibody production, and subsequently loss of response as the primary cause of immunotherapy failure in IBD patients. The benefits of shifting from the “standard” empirical dose escalation approach to therapeutic drug monitoring with anti-TNFα therapy is explored.RECENT FINDINGS:The American Gastroenterology Association and British Society of Gastroenterology both currently recommend the use of reactive therapeutic drug monitoring to guide treatment, following loss of response in inflammatory bowel disease patients with active disease. However, further research is required to prove the efficacy of a proactive therapeutic drug monitoring approach alone in remitted IBD patients.SUMMARY:A combination of personalised monitoring approach for anti-drug antibodies and therapeutic drug monitoring could provide beneficial treatment outcome for people with inflammatory bowel disease by predicting drug failure prior to clinical symptoms and allowing timely switching to an alternative drug.
Human Antibodies – IOS Press
Published: Nov 22, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.